The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Merck
First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study.
 
Yohann Loriot
Honoraria - Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Immunomedics; Janssen; Janssen (Inst); MSD Oncology; MSD Oncology (Inst); Roche; Seagen; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); CureVac (Inst); Exelixis (Inst); Incyte (Inst); Janssen Oncology (Inst); Medivation (Inst); MSD Oncology (Inst); Nektar (Inst); Oncogenex (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen
 
Petros Grivas
Consulting or Advisory Role - 4D Pharma; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Dyania Health; EMD Serono; Exelixis; Genentech; GlaxoSmithKline; Guardant Health; Immunomedics; Infinity Pharmaceuticals; Janssen; Merck; Mirati Therapeutics; Pfizer; QED Therapeutics; Regeneron; Roche; Seagen
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); EMD Serono (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Kure It Cancer Research (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst)
 
Ronald De Wit
Honoraria - Astellas Pharma; Merck Sharp & Dohme; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Merck Sharp & Dohme; Orion; Sanofi
Research Funding - Bayer (Inst); Sanofi (Inst)
 
Arjun Vasant Balar
Honoraria - AstraZeneca/MedImmune; Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca/MedImmune; Cerulean Pharma; Dragonfly Therapeutics; Genentech/Roche; GlaxoSmithKline; Incyte; Merck; Nektar; Pfizer/EMD Serono; Seattle Genetics/Astellas
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Merck (Inst); Seagen
 
Arlene O. Siefker-Radtke
Consulting or Advisory Role - AstraZeneca; Basilea; Bavarian Nordic; Bristol-Myers Squibb; EMD Serono; Genentech; Janssen; Merck; Mirati Therapeutics; NCCN; Nektar; Seagen
Research Funding - Basilea; BioClin Therapeutics; Bristol-Myers Squibb; Janssen; Merck Sharp & Dohme; Michael and Sherry Sutton Fund for Urothelial Cancer; Nektar; NIH; Takeda
Patents, Royalties, Other Intellectual Property - Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.
 
Jakub Zolnierek
Honoraria - Ipsen; Janssen; Merck; Pfizer
Consulting or Advisory Role - Amgen; AstraZeneca; Merck
 
Tibor Csoszi
Consulting or Advisory Role - Novartis
Speakers' Bureau - Ipsen; Janssen-Cilag
Travel, Accommodations, Expenses - Pfizer; Sanofi
 
Sang Joon Shin
No Relationships to Disclose
 
Se Hoon Park
Honoraria - Merck; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Janssen Oncology
Research Funding - Ono Pharmaceutical; Sanofi
 
Vagif Atduev
No Relationships to Disclose
 
Mahmut Gumus
Honoraria - MSD Oncology (Inst)
Consulting or Advisory Role - Amgen (Inst); Gen (Inst); Lilly (Inst); Novartis (Inst); Roche
Speakers' Bureau - MSD Oncology (Inst); Novartis (Inst); Polipharma (Inst); Roche (Inst)
Research Funding - Amgen (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Yu-Li Su
Honoraria - Amgen; AstraZeneca; Foundation Medicine; Ipsen; Ipsen; Merck Serono; MSD Oncology; Ono Pharmaceutical; Roche
Consulting or Advisory Role - Ipsen; MSD Oncology; Ono Pharmaceutical
Research Funding - Ono Pharmaceutical
 
Saziye Burcak Karaca
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis
Research Funding - MSD; Novartis
 
Hernan Cutuli
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen; MSD Oncology
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; MSD Oncology; Pfizer
Research Funding - AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; MSD Oncology; Pfizer
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Janssen; MSD
 
Mehmet Nahit Sendur
No Relationships to Disclose
 
Calvin Jia
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Karen O'Hara
Employment - Eisai
 
Sonia Franco
No Relationships to Disclose
 
Nobuaki Matsubara
Honoraria - Bayer; Chugai Pharma (Inst); Janssen
Consulting or Advisory Role - Amgen; AstraZeneca; Janssen; Lilly; Sanofi
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Eisai (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Takeda (Inst)